October means many things: the real start of Fall, a nudge that the holidays are just around the corner and the year is headed toward the finish line. In October, we also see the reemergence of the pink ribbon, a reminder that breast cancer can affect anyone, and the fight to find new treatments and… Read More »
It’s no secret that Bristol-Myers Squibb’s investors are feeling skittish after a pair of negative Opdivo developments last week. And on Thursday’s third-quarter conference call, executives plunged right into their doubts. After a two-day period in which the company 1) saw competitive kidney cancer data posted by Opdivo archrival Keytruda from Merck and 2) produced… Read More »
Nanotechnology is booming, and not just in the lab. In recent years, industry has embraced the unique properties of tiny particles in everything from medicine to airplane design to doughnut frosting. Philip Demokritou is an associate professor of aerosol physics and director of the Harvard T.H. Chan School of Public Health’s Center for Nanotechnology and… Read More »